United Therapeutics Corporation Earnings

United Therapeutics Corporation’s revenue jumped 17.22% since last year same period to $794.4Mn in the Q1 2025. On a quarterly growth basis, United Therapeutics Corporation has generated 7.95% jump in its revenue since last 3-months.

United Therapeutics Corporation’s net profit jumped 5.09% since last year same period to $322.2Mn in the Q1 2025. On a quarterly growth basis, United Therapeutics Corporation has generated 6.94% jump in its net profits since last 3-months.

United Therapeutics Corporation’s net profit margin fell -10.35% since last year same period to 40.56% in the Q1 2025. On a quarterly growth basis, United Therapeutics Corporation has generated -0.94% fall in its net profit margins since last 3-months.

United Therapeutics Corporation’s price-to-earnings ratio after this Q1 2025 earnings stands at 11.63.

United Therapeutics Corporation’s earning per share (EPS) estimates for the current quarter stand at 7.35 - a 10.36% jump from last quarter’s estimates.

United Therapeutics Corporation’s earning per share (EPS) estimates for the current year stand at 7.35.

United Therapeutics Corporation’s earning per share (EPS) jumped 7.45% since last year same period to 6.63 in the Q1 2025. This indicates that the United Therapeutics Corporation has generated 7.45% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. United Therapeutics Corporation’s return on assets (ROA) stands at 0.13.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. United Therapeutics Corporation’s return on equity (ROE) stands at 0.2.